Dual use of amphiphilic macromolecules as cholesterol efflux triggers and inhibitors of macrophage athero-inflammation

Biomaterials

Volumn 32, Issue 32, 2011, Pages 8319-8327

  Iverson, Nicole M ^a   Plourde, Nicole M ^b   Sparks, Sarah M ^c   Wang, Jinzhong ^c   Patel, Ekta N ^b   Shah, Pratik S ^a   Lewis, Daniel R ^a   Zablocki, Kyle R ^a   Nackman, Gary B ^d   Uhrich, Kathryn E ^c   Moghe, Prabhas V ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b The State University of New Jersey   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Copolymers; Drug delivery; Inflammation; Low density lipoproteins; Macrophage

Indexed keywords

ALIPHATIC CHAINS; AMPHIPHILIC MACROMOLECULES; ARTERIAL DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BASAL LEVELS; BINDING ACTIVITIES; BIOACTIVE MACROMOLECULES; CAROTID ARTERY; CHOLESTEROL ACCUMULATION; CHOLESTEROL EFFLUX; DIVERSE FEATURES; DUAL USE; HIGH-FAT DIET; IN-VITRO; IN-VIVO; INFLAMMATION; INTRACELLULAR CHOLESTEROL; LOW DENSITY LIPOPROTEINS; MUCIC ACIDS; SCAVENGER RECEPTOR; SMALL MOLECULES; SPRAGUE-DAWLEY RATS; THERAPEUTIC INTERVENTION; VASCULAR WALL;

CHOLESTEROL; DRUG DELIVERY; ETHYLENE; GLYCOLS; LIPIDS; MACROPHAGES; PATHOLOGY; POLYETHYLENE GLYCOLS;

MACROMOLECULES;

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ALIPHATIC COMPOUND; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOMATERIAL; CARBON; CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL; MUCIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY INJURY; CELL LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMBRYO; ENCAPSULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIPID DIET; MACROMOLECULE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MACROMOLECULAR SUBSTANCES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; NANOPARTICLES; ORPHAN NUCLEAR RECEPTORS; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SCAVENGER RECEPTORS, CLASS A; SURFACE-ACTIVE AGENTS;

RATTUS;

EID: 80052372756     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.039     Document Type: Article

References (46)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T., Flegal K., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009, 119:480-486.
2. McKenney J.M. Lipid management: tools for getting to the goal. Am J Manag Care 2001, 7:S299-S306.
3. Gotto A.M. Statins: powerful drugs for lowering cholesterol. Circulation 2002, 105:1514-1516.
4. Babaev V., Gleaves L., Carter K., Suzuki H., Kodama T., Fazio S., et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 2000, 20:2593-2599..
5. Febbraio M., Sheibani N., Schmitt D., Silverstein R., Hajjar D., Cohen P., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105:1095-1108.
6. Fujiwara Y., Kiyota N., Hori M., Matsushita S., Iijima Y., Aoki K., et al. Esculeogenin a, a new tomato sapogenol, ameliorates hyperlipidemia and atherosclerosis in Apo-E-deficient mice by inhibiting acat. Arterioscler Thromb Vasc Biol 2007, 27:2400-2406.
7. Manning-Tobin J.J., Moore K.J., Seimon T.A., Bell S.A., Sharuk M., Alvarez-Leite J.I., et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2009, 29:19-26.
8. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995, 57:791-804..
9. Yamakawa T., Ogihara K., Nakamura M., Utsunomiya H., Kadonosono K., Kishikawa S., et al. Effect of dehydroepiandrosterone on atherosclerosis in Apolipoprotein E-deficient mice. J Atheroscler Thromb 2009, 16:501-508..
10. Tao L., Uhrich K.E. Novel amphiphilic macromolecules and their in vitro characterization as stabilized micellar drug delivery systems. J Colloid Interface Sci 2006, 298:102-110.
11. Geyeregger R., Zeyda M., Stulnig T.M. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006, 63:524-539..
12. Aravindhan K., Webb C., Jaye M., Ghosh A., Willette R., DiNardo N.J., et al. Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. J Lipid Res 2006, 47:1250-1260.
13. Tangirala R., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., et al. Identification of macrophage liver-X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002, 2002(99):11896-11901.
14. Tontonoz P., Mangelsdorf D.J. Liver-X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003, 17:985-993.
15. Iverson N.M., Sparks S.M., Demirdirek B., Uhrich K.E., Moghe P.V. Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers. Acta Biomater 2010, 6:3081-3091.
16. Djordjevic J., del Rosario L., Wang J., Uhrich K. Amphiphilic scorpion-like macromolecules as micellar nanocarriers. J Bioact Compat Polym 2008, 23:532-551.
17. Tian L., Yam L., Zhou N., Tat H., Uhrich K.E. Amphiphilic scorpion-like macromolecules: design, synthesis, and characterization. Macromolecules 2004, 37:538-543.
18. Iverson N., Sparks S.M., Demirdirek B., Uhrich K.E., Moghe P.V. Controllable inhibition of cellular uptake of oxidized low density lipoprotein: structure-property relationships for nanoscale amphiphilic macromolecules. Acta Biomater 2010, 6:3081-3091.
19. Chang M., Potter-Perigo S., Wight T., Chait A. Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices. J Lipid Res 2001, 42:824-833.
20. Oorni K., Pentikainen M.O., Annila A., Kovanen P.T. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J Biol Chem 1997, 272:21303-21311.
21. Chnari E., Lari H., Tian L., Uhrich K., Moghe P. Nanoscale anionic macromolecules for selective retention of low-density lipoproteins. Biomaterials 2005, 26:3749-3758.
22. Chnari E., Nikitczuck J., Wang J., Uhrich K., Moghe P. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoproteins uptake and atherogenesis in macrophages. Biomacromolecules 2006, 7:1796-1805.
23. Mani Feasibility of in vivo identification of endogenous ferritin with positive contrast mri in rabbit carotid crush injury using grasp. Magn Reson Med 2006, 56:1096-1106.
24. Wang J., Plourde N.M., Iverson N., Moghe P.V., Uhrich K.E. Nanoscale amphiphilic macromolecules as lipoprotein inhibitors: the role of charge and architecture. Int J Nanomedicine 2007, 2:697-705.
25. Plourde N.M., Kortagere S., Welsh W., Moghe P.V. Structure-activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor a. Biomacromolecules 2009, 10:1381-1391.
26. Virella G., Munoz J., Galbraith G., Gissinger C., Chassereau C., Lopes-Virella M. Activation of human monocyte-derived macrophage by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol 1995, 75:179-189.
27. Lusis A.J. Atherosclerosis Nat 2000, 407:233-241.
28. Goldstein J., Ho Y., Basu S., Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979, 76:333-337.
29. de Winther M., van Dijk K., Havekes L., Hofker M. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:290-297.
30. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 1997, 8:275-280.
31. Aravindhan K., Webb C.L., Jaye M., Ghosh A., Willette R.N., DiNardo N.J., et al. Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. J Lipid Res 2006, 47:1250-1260.
32. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
33. Geng Y.J., Holm J., Nygren S., Bruzelius M., Stemme S., Hansson G.K. Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma. Arterioscler Thromb Vasc Biol 1995, 15:1995-2002.
34. Luoma J., Hiltunen T., Sarkioja T., Moestrup S.K., Gliemann J., Kodama T., et al. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994, 93:2014-2021.
35. Chnari E., Nikitczuk J.S., Wang J., Uhrich K.E., Moghe P.V. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 2006, 7:1796-1805.
36. Platt N., Gordon S. Is the class a macrophage scavenger receptor (SR-A) multifunctional? - the mouse's tale. J Clin Invest 2001, 108:649-654.
37. Khanna A.K. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. J Biomed Sci 2009, 16.
38. Hansson G. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
39. Schreyer S.A., Peschon Jacques J., LeBoeuf Renee C. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996, 271:26174-26178.
40. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
41. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., et al. Ligand activation of LXR-β reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR-α and Apo-E. J Clin Invest 2007, 117:2337-2346.
42. Joseph S.B., McKilligin E., Pei L., Watson M., Collins A., Laffitte B., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
43. Joseph S.B., Tontonoz P. LXRs: new therapeutic targets in atherosclerosis?. Curr Opin Pharmacol 2003, 3:192-197.
44. Albers M., Blume B., Schlueter T., Wright M., Kober I., Kremoser C., et al. A novel principle for partial agonism of liver-X receptor ligands. J Biol Chem 2006, 281:4920-4930.
45. Kunjathoor V., Febbraio M., Podrez E., Moore K., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002, 277:49982-49988.
46. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.